Trial Profile
A study to investigate HTI Immunogen (HIV vaccine) for the treatment of patients with HIV infection
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2016
Price :
$35
*
At a glance
- Drugs HTI immunogen (Primary)
- Indications HIV infections
- Focus Proof of concept; Therapeutic Use
- 20 Jan 2016 New trial record
- 11 Jan 2016 This trial is expected to begin in the third quarter of 2016, according to an Aelix Therapeutics media release.